{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:24:12Z","timestamp":1790835852618,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T00:00:00Z","timestamp":1443139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T00:00:00Z","timestamp":1443139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2015.80","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T13:21:44Z","timestamp":1443187304000},"page":"e350-e350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma"],"prefix":"10.1038","volume":"5","author":[{"given":"C","family":"Papayannidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D J","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M N","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ozeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Aster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P D","family":"Lira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K R","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K A","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,25]]},"reference":[{"key":"BFbcj201580_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","volume":"1","author":"AA Ferrando","year":"2002","unstructured":"Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75\u201387.","journal-title":"Cancer Cell"},{"key":"BFbcj201580_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robinson LL, Look AT . Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030\u20131043.","journal-title":"Lancet"},{"key":"BFbcj201580_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/path.2789","volume":"223","author":"JC Aster","year":"2011","unstructured":"Aster JC, Backlow SC, Pear WS . Notch signaling in T cell lymphoblastic leukemia\/lymphoma and other hematological malignancies. J Pathol 2011; 223: 262\u2013273.","journal-title":"J Pathol"},{"key":"BFbcj201580_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/01.moh.0000143965.90813.70","volume":"11","author":"WS Pear","year":"2004","unstructured":"Pear WS, Aster JC . T cell acute lymphoblastic leukemia\/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling. Curr Opin Hematol 2004; 11: 426\u2013433.","journal-title":"Curr Opin Hematol"},{"key":"BFbcj201580_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/sj.leu.2404258","volume":"20","author":"T Palomero","year":"2006","unstructured":"Palomero T, Barnes KC, Real PJ, Glade-Bender JL, Sulis ML, Murty VV et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma secretase inhibitors. Leukemia 2006; 20: 1279\u20131287.","journal-title":"Leukemia"},{"key":"BFbcj201580_CR6","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/0008-5472.CAN-06-3958","volume":"67","author":"I Shi","year":"2007","unstructured":"Shi I, Wang TL . Notch signalling, gamma-secretase inhibitors and cancer therapy. Cancer Res 2007; 67: 1879\u20131882.","journal-title":"Cancer Res"},{"key":"BFbcj201580_CR7","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1182\/blood-2008-02-138172","volume":"113","author":"F Armstrong","year":"2009","unstructured":"Armstrong F, Brunet de la Grange P, Gerby B, Rouyez MC, Calvo J, Fontenay M et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009; 113: 1730\u20131740.","journal-title":"Blood"},{"key":"BFbcj201580_CR8","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1158\/1535-7163.MCT-10-0034","volume":"9","author":"P Wei","year":"2010","unstructured":"Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010; 9: 1618\u20131628.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj201580_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1158\/1535-7163.MCT-11-0938","volume":"11","author":"JB Samon","year":"2012","unstructured":"Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J et al. Preclinical analysis of the \u03b3-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012; 11: 1565\u20131575.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj201580_CR10","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1158\/1078-0432.CCR-12-1379","volume":"18","author":"CC Zhang","year":"2012","unstructured":"Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z et al. Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor PF-03084014 in breast cancer models. Clin Cancer Res 2012; 18: 5008\u20135019.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201580_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccr.2007.10.027","volume":"12","author":"A Gutierrez","year":"2007","unstructured":"Gutierrez A, Look AT . NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 2007; 12: 411\u2013413.","journal-title":"Cancer Cell"},{"key":"BFbcj201580_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nm1636","volume":"13","author":"T Palomero","year":"2007","unstructured":"Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203\u20131210.","journal-title":"Nat Med"},{"key":"BFbcj201580_CR13","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1200\/jco.2006.24.18_suppl.6585","volume":"24","author":"DJ DeAngelo","year":"2006","unstructured":"DeAngelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006; 24: 6585.","journal-title":"J Clin Oncol"},{"key":"BFbcj201580_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.blre.2010.09.004","volume":"25","author":"M Paganin","year":"2011","unstructured":"Paganin M, Ferrando A . Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011; 25: 83\u201390.","journal-title":"Blood Rev"},{"key":"BFbcj201580_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","volume":"21","author":"WA Messersmith","year":"2015","unstructured":"Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B et al. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral \u03b3-secretase inhibitor PF-03084014. Clin Cancer Res 2015; 21: 60\u201367.","journal-title":"Clin Cancer Res"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201580","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T10:02:49Z","timestamp":1672912969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,25]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9]]}},"alternative-id":["BFbcj201580"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2015.80","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,25]]},"assertion":[{"value":"25 September 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CP, DJD, WS, FK, GG-M and GM have no relevant disclosures. JCA is a consultant for Cell Signaling Technology and CytomX, Inc. BH, NMS, RC, XZ, JMR, PAE, MO, DH, PDL, KRM and KAK were full-time employees of Pfizer during the conduct of this study. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}